Wantstats
Company ProfilePremium

ALMIRALL, S.A.

Company Profile Analysis

Book DemoRegister Your Interest
ESOMAR 23 Corporate BadgeISO Certifications Badge
ALMIRALL, S.A. - Healthcare showcase

Year Founded & Workforce

1943

1,805 Employees

Industry

Healthcare

Services

AknemycinAkneroxidActikerallAknenorminAmciderm
A

ALMIRALL, S.A. Employee Contacts

55 verified contactsNames, job titles, seniority and locations

View Employee Contacts

ALMIRALL, S.A. Overview

Company Headquarters: Maine, US

Founded: 1943

Workforce: 1,805

Company Working:

Almirall, S.A. is a pharmaceutical company. It engaged in research, development, manufacturing, and commercialization of medicines and licensed products. The company offers some of the major brands in the market, including the Ciclopoli franchise, Solaraze, Decoderm franchise, Skilarence, among others. The company’s products focus on treating respiratory diseases, including asthma and chronic obstructive pulmonary disease (COPD), autoimmune diseases including rheumatoid arthritis and multiple sclerosis, dermatological diseases including psoriasis, eczema, acne, and other skin infections, and gastrointestinal diseases including irritable bowel syndrome with constipation.

Strategy

Almirall, S.A focuses on increasing its footprints globally by establishing its manufacturing, research and development, and commercial operations in many regions across the world. To do this, the company is highly involved in the strategic agreement or partnership with other firms. The company aims to develop and grow its R&D pipeline to address highly underserved diseases within oncodermatology and immunodermatology.

Company Snapshot

$854.1M

Revenue

1,805

Employees

1943

Founded

Maine, US

Headquarters

SWOT Analysis

Strengths

  • Global presence
  • Strong R&D
  • Skilled workforce
  • Wide distribution network
  • Large consumer base
  • High consumer satisfaction

Weaknesses

  • Quality of products
  • Price of products
  • Supply demand gap due to poor forecasting abilities
  • Major dependency on the European market for revenue generation

Opportunities

  • Growth in dermatology and medical aesthetics areas
  • Leading dermatology therapy
  • Entering emerging markets
  • Collaboration with the public sector institutes
  • Targeting new customers through online channels

Threats

  • Government regulations
  • Climate change risk
  • Strict government regulations
  • Fluctuations in foreign exchange rates

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateApproachDevelopment
December 2017PartnershipAlmirall S.A. and Athenex entered into a strategic partnership to develop and commercialize KX2-391 in the US and Europe for the treatment of actinic keratosis.
February 2020AgreementAlmirall signed a license agreement with Paratek Pharmaceuticals, Inc. for the development of Seysara in China.
January 2019Product LaunchAlmirall announced the launch of Seysara, a novel tetracycline-derived oral antibiotic and the first to be developed specifically for the treatment of acne. The product is commercially launched in the US market.
October 2018ApprovalAlmirall received the FDA approval for Seysara (sarecycline) an oral antibiotic for the treatment of moderate to severe acne vulgaris in patients 9 years of age and older.
September 2018AcquisitionAlmirall acquired Allergan's Medical Dermatology unit in the US. The acquisition enhanced the former’s dermatology portfolio.

Product Offering

  • ALMIRALL, S.A.
    • Aknemycin
    • Akneroxid
    • Actikerall
    • Aknenormin
    • Amciderm
    • Aknemycin Plus
    • Aknosan
    • Others
    • Acne Treatment

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

By Business Segment: Sales rose from USD 854.1 Mn in 2017 to USD 1,018 Mn in 2019.
ALMIRALL, S.A. — By Business Segment
Series (USD Mn)201720182019
Sales854.1957.81,018
R&D Expenditure99.3103.5103

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.

Get Contacts →